HAL (France)
open access
Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma#146261
- Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma#461036
- Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer#1114941
- CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy#898097
- Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012#833789
Record · ID 476014
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive